Reports Q4 revenue $196.87M, consensus $201.93M. “2025 was a year of disciplined execution for Pacira (PCRX). With the launch of our 5×30 strategy, we reignited momentum across the business and delivered strong, measurable progress. Our products benefitted more than 2.5 million patients, generated $726 million in revenue, and achieved the highest gross margins in our company’s history. Together, these results clearly validate the impact and promise of our 5×30 strategy,” said Frank D. Lee, chief executive officer of Pacira BioSciences.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- PCRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Pacira Biosciences (PCRX) Securities Lawsuit Dismissed by New Jersey Federal Court
- Pacira highlights new NOPAIN act survey data conducted by Voices
- Pacira reports inducement grants under Nasdaq listing rule
- Pacira BioSciences adds seasoned leader to board